Announcement on Voluntary Disclosure of the Entry of the Human Papillomavirus15-valent Vaccine (Escherichia Coli) into Phase II Clinical Trials

About this update from Liaoning Chengda Biotechnology Co. Ltd. Class A

Announcement on Voluntary Disclosure of the Entry of the Human Papillomavirus15-valent Vaccine (Escherichia Coli) into Phase II Clinical TrialsThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Liaoning Chengda Biotechnology Co. Ltd. Class A